ABOUT THE RESEARCH
This period provides a sizeable group of biotech listings, with several years to observe what happened afterwards. The frame has 452 companies: 349 in North America and 103 in Europe. The listing window ends in 2021; outcomes are followed through 25 September 2026.
They are public documents that name directors, major shareholders and the connections between them. The ownership footnotes help establish which investor a director represents. SEC filings cover the US-listed companies; European home-listed companies required other sources.
The question concerns what happens after an IPO. Listing provides a common starting point and detailed disclosures. Private companies, and companies acquired before completing an IPO, fall outside this study.